The use of neuromuscular blocking agents in the ICU: where are we now?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23591211.
- Also identified by DOI 10.1097/CCM.0b013e31828ce07c.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intensivists use neuromuscular blocking agents for a variety of clinical conditions, including for emergency intubation, acute respiratory distress syndrome, status asthmaticus, elevated intracranial pressure, elevated intra-abdominal pressure, and therapeutic hypothermia after ventricular fibrillation-associated cardiac arrest. The continued creation and use of evidence-based guidelines and protocols could ensure that neuromuscular blocking agents are used and monitored appropriately. A collaborative multidisciplinary approach coupled with constant review of the pharmacology, dosing, drug interactions, and monitoring techniques may reduce the adverse events associated with the use of neuromuscular blocking agents.
Medical subject headings
- Critical Care
- Intensive Care Units
- Neuromuscular Blocking Agents